Skip to content

Comparison of Clinical and Radiographic Evaluation of the Effect of Decalcified Freeze Dried Bone Allograft(DFDBA) with Amniotic Membrane and Decalcified Freeze Dried Bone Allograft (DFDBA) with Platelet Rich Fibrin(PRF) Membrane in the Treatment of Intrabony Defects in Periodontitis Patients

Comparative Clinical and Radiographic Evaluation of the Effect of Decalcified Freeze Dried Bone Allograft (DFDBA) with Amniotic Membrane and Decalcified Freeze Dried Bone Allograft (DFDBA) with Platelet Rich Fibrin (PRF) as Membrane in the Treatment of Intrabony Defects in Chronic Periodontitis Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/012987
Enrollment
40
Registered
2018-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Periodontitis patients with interproximal bone defects of 5mm or more

Interventions

Intervention1: Decalcified Freeze Dried Bone Allograft (DFDBA) with Amniotic Membrane: Commercially available DFDBA and Amniotic Membrane Control Intervention1: Decalcified Freeze Dried Bone Allograft

Sponsors

Geetika Prabhakar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1).Age group between 20-60years 2).Diagnosis with chronic periodontitis 3).Patients in good systemic health with no contraindication to periodontal surgery 4).Patients having Intrabony defects with pocket depths of >5mm and with radiographic evidence of vertical / angular bone loss in the affected sites. 5).Involved teeth to be vital and asymptomatic.

Exclusion criteria

Exclusion criteria: 1).One â?? wall osseous defects. 2).Patients suffering from any systemic diseases or with compromised immune system. 3).Patients who had received any type of periodontal therapy for the past 6 months 4).Patients taking any immuno-suppressive drugs like corticosteroids 5).Patients with a known history of allergy to doxycycline or Chlorhexidine or any other medicine are used in the study. 6).Patients showing unacceptable oral hygiene compliance during / after the phase I therapy. 7).Patients taking any drug known to cause gingival enlargement. 8).Pregnant and/or lactating mothers. 9).Patients who were smokers or had tobacco in any other form. 10).Endodontically treated teeth. 11).Patient on anticoagulant therapy 12).Patient with bleeding disorders.

Design outcomes

Primary

MeasureTime frame
1. Plaque Index (P.I.) (SILNESS AND LOE, 1964) 2. Gingival Index (G.I.) (LOE &SILNESS, 1963). 3. Probing Pocket Depth (PPD). 4. Clinical Attachment Level (CAL). 5.Radiographic Bone fill will be evaluated using intra oral periapical radiograph of the surgical site.Timepoint: clinical evaluation at baseline, 1 month, 3 months and 6 months after surgery. Radiographic evaluation at baseline, immediate post surgery and 6 months post surgery.

Secondary

MeasureTime frame
1. Plaque Index (P.I.) (SILNESS AND LOE, 1964) 2. Gingival Index (G.I.) (LOE &SILNESS, 1963). 3. Probing Pocket Depth (PPD). 4. Clinical Attachment Level (CAL). 5.Radiographic Bone fill will be evaluated using intra oral periapical radiograph of the surgical site.Timepoint: clinical evaluation at baseline, 1 month, 3 months and 6 months after surgery. Radiographic evaluation at baseline, immediate post surgery and 6 months post surgery.

Countries

India

Contacts

Public ContactGeetika Prabhakar

Nair Hospital Dental College

maladixit25@gmail.com02223082714

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026